No, amlodipine is not a beta-blocker
Amlodipine is a dihydropyridine calcium channel blocker (CCB), not a beta-blocker. These are two completely different drug classes with distinct mechanisms of action 1.
Mechanism of Action
Amlodipine works by inhibiting calcium ion influx across cell membranes in vascular smooth muscle, causing peripheral arterial vasodilation and blood pressure reduction 1. It acts as a peripheral arterial vasodilator with minimal direct effects on heart rate or cardiac conduction 1.
In contrast, beta-blockers work by blocking beta-adrenergic receptors, reducing heart rate and cardiac contractility through a completely different mechanism.
Key Distinguishing Features
Amlodipine's pharmacologic profile clearly differentiates it from beta-blockers:
- No effect on heart rate or AV conduction: Unlike beta-blockers, amlodipine does not change sinoatrial nodal function or atrioventricular conduction 1
- Peripheral vasodilation: Produces marked peripheral arterial vasodilation, which is characteristic of dihydropyridine CCBs, not beta-blockers 2
- Can be safely combined with beta-blockers: Clinical studies demonstrate that amlodipine can be administered in combination with beta-blockers without adverse electrocardiographic effects 1, which would not make sense if it were itself a beta-blocker
Clinical Classification
Multiple authoritative guidelines consistently classify amlodipine as a long-acting dihydropyridine calcium channel blocker alongside other CCBs like nifedipine and felodipine, while listing beta-blockers as a separate drug class 3, 4, 5, 6.
The 2018 Hypertension Canada guidelines explicitly list these as distinct first-line monotherapy options: thiazide diuretics, beta-blockers, ACE inhibitors, ARBs, and long-acting calcium channel blockers (CCBs) 3.